Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers (DDD13DICLO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers
- Age 20 - 35 years
Exclusion Criteria:
- Illness
- Acute / Chronic gastric disorder
- Use of medicine
- (possible) pregnancy
- Frequent exposure to X-rays during the past year
- HIV / Hepatitis B Virus or Hepatitis C Virus infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Nutritional State
Fed vs. Fasted State Diclofenac potassium 50 mg |
Diclofenac potassium 50 mg
Other Names:
|
|
Active Comparator: Use of a PPI
Nexiam (esomeprazole) 40 mg Diclofenac potassium 50 mg |
Diclofenac potassium 50 mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Area under the Concentration - Time Curve
Time Frame: Every 10 minutes for 2 h
|
Every 10 minutes for 2 h
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Diclofenac
Other Study ID Numbers
Other Study ID Numbers
- EudraCT 2013-004636-29
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Supersaturation and Precipitation in the Stomach
-
NCT06899633Active, not recruitingDescription of SLE Activity in Patients in Routine Practice in the Republic of Kazakhstan | Description of the Course of SLE in Patients in the Republic of Kazakhstan | Description of Methods and Approaches to the Treatment of Patients With SLE in the Republic of Kazakhstan
-
NCT07245095RecruitingEsophagogastroduodenoscopy | Premedication | Gastritis Associated With Helicobacter Pylori | Simethicone | Esophagogastroduodensocopy (EGD) Procedure | Tumor Gastric | Lesions in the Esophagus, Stomach, Duodenum or Rectum | Placebo - Control | Visualization | N-Acetylcysteine
-
NCT05634018Not yet recruitingthe Strength Properties of the Aorta in Vivo | the Strength Properties of the Aorta in Vitro | Regression Model of Aortic Strength Properties in Vitro and in Vitro
-
NCT01916421CompletedPancreatic or Peripancreatic Lesions | Lesions in the Esophagus, Stomach, Duodenum or Rectum | Mediastinal ( Chest) Masses | Enlarged Lymph Nodes
-
NCT06044961CompletedPatients With Locally Advanced Carcinoma of the Stomach and Oesophagogastric Junction
-
NCT06272019CompletedThe Retention of Iodine in Saliva Over the Time | The Comparison of Iodine in Saliva Between Gargle and Swab
-
NCT01528215CompletedPartial Edentulism in the Maxilla or in the Mandible
-
NCT01183559CompletedCancer of the Esophagus | Adenocarcinoma of the Gastroesophageal Junction | Cancer of the Stomach
-
NCT06675136RecruitingMetastatic Gastric Adenocarcinoma | Clinical Stage IVB Gastric Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Peritoneum
-
NCT02008825UnknownEnhance Delineation of the Stomach Anatomy and the Surgeon's Appreciation of the Extent of Gastric Volume to be Removed; | Increase the Safety Profile of the Patient (i.e., Reduce the Likelihood of Accidental Stapling of the Orogastric Tube or Bougie); | Reduce the Incidence of OR Contamination/Infection Transmission; | Streamline OR Workflow, Resulting in Reduced OR Time | Ensure Consistent and Reproducible Staple Lines.
Clinical Trials on Diclofenac potassium 50 mg
-
NCT05082662CompletedBioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated TabletAnalgesic | Non-steroidal Anti-inflammatory (NSAID) | Antipyretic
-
NCT00474136Completed
-
NCT00914160Completed
-
NCT05626140CompletedSciatica | Sciatica Acute
-
NCT05211154TerminatedMigraine Without Aura | Migraine With Aura
-
NCT07453784Recruiting
-
NCT05981040Completed
-
NCT00913224Completed
-
NCT02373930CompletedInfection, Human Immunodeficiency Virus